Short answer
AGIOS PHARMACEUTICALS, INC. (AGIO) filed an 8-K current report with the SEC on June 18, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). Stockholders approved 2,000,000 additional shares under Agios’s 2023 Stock Incentive Plan.
AGIOS PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Stockholders approved 2,000,000 additional shares under Agios’s 2023 Stock Incentive Plan
- Incentive stock-option capacity also increased by 2,000,000 shares
- Expanded equity pool supports employee and executive retention but creates potential shareholder dilution
- Amended plan terms detailed in proxy pages 90–103 and Exhibit 99.1
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Rahul Ballal, Brian Goff and Cynthia Smith elected as Class I directors through 2029
- Cynthia Smith faced 14,592,704 withheld votes, indicating comparatively weaker shareholder support
- Executive compensation approved by 43,396,045 votes, supporting current pay practices
- 2023 Plan Amendment approved by 43,549,751 votes, preserving expanded equity-compensation flexibility
- PwC ratified as independent auditor by 48,511,213 votes, reinforcing auditor continuity
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AGIOS PHARMACEUTICALS, INC. 8-K filings
Get the next AGIO 8-K as it lands
Follow AGIO for push alerts, or ask the research agent what this filing means.